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Additional Sample Information. Dilute labels and human/rat mixtures were prepared by mixing stock solutions in the desired ratios before drying under nitrogen.
Human amylin aggregated in the presence of rat amylin inhibitor was allowed to mature for 8 hours before spectra were recorded. A similar procedure was followed for the sample in which rat amylin was added to mature fibrils: aliquots of human and rat amylin stock solutions were dried under nitrogen in separate tubes. Human amylin was then reconstituted in buffer, allowed to mature for 3 hours and finally this solution was used to reconstitute the dried rat amylin peptide before adding to a sample cell. The data are reproducible over the course of several months (see Supplementary Figs . S4-7). Thus, sample heterogeneity, which is sometimes problematic in amyloid studies, is not an issue. Under the conditions used here we do not observe a lag phase during the time course of amyloid formation by the human peptide. This is not surprising because the lag phase can be concentration dependent and the experiments were conducted using 1 mM peptide which is required for our studies, but is higher than used in other studies.
Label Frequency Analysis. Isotope label peak frequencies were by obtained through fitting. First, a diagonal slice through each spectrum was taken from ~1541-1620 cm -1 , the spectral region containing the label peak and the unlabeled β-sheet peak. The diagonal slice was then fit to a sum of two Gaussian functions. In a few cases, as needed, a constant offset was also included and fixed at the experimental value. Fitting was performed using a nonlinear least-squares optimization.
Difference 2D IR Spectra. In order to isolate Ala13 label feature of interest in
Figs. 3e, 3f, 3g and 3h, a corresponding spectrum containing unlabeled peptide was subtracted from the spectrum containing labeled peptide. For example, in order to isolate the Ala13 feature of rat amylin, Fig. 3e is shown as the difference of spectra for two samples, both containing Ala13-labeled human amylin but one containing Ala13-labeled rat amylin and the second containing unlabeled rat amylin. Similarly, for Fig. 3f , both samples contained unlabeled human amylin but one contained Ala13-labeled rat amylin and the second containing unlabeled rat amylin. For Fig. 3g , both samples contained unlabeled rat amylin but one contained Ala13-labeled human amylin and the second containing unlabeled human amylin. For Fig. 3h , both samples contained unlabeled human amylin but one contained Ala13-labeled rat amylin and the second containing unlabeled rat amylin. In all cases, the two samples that made up each difference spectra were prepare simultaneously and identically, and the two spectra were measured backto-back under the same conditions.
Thioflavin-T Binding Kinetics. Thioflavin-T assays have previously been used
to study the effects of rat amylin inhibition on fibril growth. 1 In that work, kinetics were only monitored for a few hours and concentrations of 16-160 µM were used. To check that rat amylin inhibited at the concentrations used in this study and to extend the kinetics to timescales comparable to 2D IR measurements, we monitored thioflavin-T Transmission Electron Microscopy Analysis. Multiple images were acquired for each sample and used for apparent width measurements ( Supplementary Fig. S10 ).
Width measurements were made in Adobe Illustrator by drawing lines across the apparent width of structures, calculating the lengths of the lines in pixels and converting to nanometers using the scale bar for each image. The locations of measurements were chosen randomly although poor contrast may have prevented identification or measurement of some structures. Due to the length of many of the structures, care was taken to measure each structure no more than once.
Molecular Dynamics Simulations.
The initial structure of human amylin fibril was taken from the solid-state NMR model of Tycko et al.
2
. The structure of rat amylin was designed to form a β-sheet structure with the residues 1 to 18 of the displaced human amylin peptide as shown in Fig. 5a . Each peptide contained a disulfide bridge between Cys2 and Cys7 and an amidated C-terminus. The GROMOS96 53a6 force field 3-5 was used to model the peptides, and the SPC model 6 was used for water molecules. This combination of force fields has been shown to lead to structures of human amylin and rat amylin in solution that are in quantitative good agreement with experimental 2D IR data 7, 8 . The side chains of charged amino acids were ionized based on their pKa values. The resulting net charge was +3 for a human amylin peptide and +2
for a rat amylin peptide. Chloride ions were added to neutralize the system. The initial configuration was generated such that water fully solvates the peptides, existing both outside and inside the fibril. Molecular dynamics simulations were conducted with the GROMACS molecular simulation package [9] [10] [11] [12] . Long-range electrostatic interactions were treated with a particle-mesh Ewald sum 13, 14 . All simulations were performed with rigid bonds (using the linear constraint solver method) and with an integration time step of 2 Fig. S1 ) do not show a frequency difference between the measurements of pure and dilute amylin. The absence of a shift indicates that these residues have couplings that are too small to be reliably measured (<2 cm -1 ), reside in region with high structural disorder, or both. Ala5 is located in a region that is constrained by a disulfide bond, which is incompatible with β-sheet formation, and does not form an order arrangement.
Ser20 resides in the partially disordered loop. Thus, a weak coupling strength and large amounts of structural disorder likely prevent significant exciton delocalization, and these residues are poor markers for monitoring inhibitor binding.
Dilute Labeling. Monte Carlo simulations were performed to determine the effect of 25% isotope dilution on the formation of linear column of labels in human amylin fibrils. In the simulation, 25% of peptides in an array of 100,000 were randomly assigned to be labeled. The simulation then stepped through the array, determined the size of each group of sequential labels, and counted the number of groups for each size. To ensure accuracy, the algorithm was checked versus manual counting for a series of small arrays of less than 50 peptides. The percentage of labels in each column size is shown in Supplementary Fig. S11 . 
